ERRATUM - LUMIBIRD: 2021 FIRST-QUARTER REVENUES
26 Aprile 2021 - 6:54PM
ERRATUM - LUMIBIRD: 2021 FIRST-QUARTER REVENUES
Lannion, April 26, 2021 – 5:45pm
2021 FIRST-QUARTER REVENUES
THE LUMIBIRD GROUP, THE EUROPEAN LEADER
FOR LASER TECHNOLOGIES, ACHIEVED
54% CONSOLIDATED REVENUE GROWTH IN THE
FIRST QUARTER OF 2021 TO €33.8M, DRIVEN BY THE INTEGRATION OF
ELLEX’S LASER AND ULTRASOUND ACTIVITIES. ON A PRO-FORMA
BASIS1, REVENUES ARE
UP +3.2% (+5.0% AT CONSTANT EXCHANGE
RATES), REFLECTING THE GRADUAL UPTURN IN BUSINESS
COMPARED WITH A FIRST QUARTER OF 2020 THAT WAS STILL RELATIVELY
UNAFFECTED BY THE IMPACTS OF THE CRISIS.
Consolidated revenues
(unaudited)
Revenues (€m) |
2021 |
2020 |
Reported change |
pro forma 2020 1 |
Pro forma 1 change |
First quarter |
33.8 |
21.9 |
+54% |
32.7 |
+3,2% |
of which |
|
|
|
|
|
Photonics |
14.6 |
13.3 |
+9.0% |
13.3 |
+9.0% |
Medical |
19.2 |
8.6 |
+124% |
19.4 |
-1.1% |
The LUMIBIRD Group’s consolidated revenues came
to €33.8m at March 31, 2021, up 54%. Compared with pro-forma 2020
revenues, including Ellex’s laser and ultrasound activities at
January 1, the year-on-year change represents +3.2% and +5.0% at
constant exchange rates, after offsetting negative foreign exchange
effects for -€0.6m. These figures are aligned with the trend from
the previous quarters, with the Medical division’s stability
(-1.1%) confirming the upturn compared with a period for comparison
that included non-recurring sales (Libya tender) for €0.85m and
that was not yet affected by the crisis, combined with progress for
the Photonics division, which is now freed up from the impact of
the legacy Defense sector contracts.
For the Photonics division, the
Industrial and Scientific business is reporting significant growth
(+25% to €6.8m), thanks in particular to the impact of OEM sales
for medical and flatscreen applications. The Lidar business is
stable (-2.0% to €3.9m), with an upturn in sales of lasers to
integrators, in particular in the field of autonomous vehicles,
offset by a contraction in sales of Lidar systems to end users,
which, like the Medical business, were affected by the cancellation
of trade shows and the travel restrictions put in place. The
Defense/Space business is stable (0% to €3.9m), with the planned
contraction on the legacy contracts in 2020 no longer resulting in
an unfavorable basis for comparison.
The Medical
division recorded +124% growth based on reported
data and -1.1% pro-forma (+5.5% excluding Libya revenues and
exchange rate impacts). These figures factor in the successful
integration of Ellex’s Laser and Ultrasound activities in a context
that was significantly affected by the health crisis in certain
countries and the ongoing situation with the main events held in
virtual format.
The synergies capitalized on between LUMIBIRD
and Ellex are continuing to deliver benefits this year,
including:
- The robust
development of glaucoma-related products, which represent a large
part of sales for Ellex and Quantel Medical, with the entire range
now sold by all of the teams worldwide. This trend has been further
strengthened with the publication of the latest EGS recommendations
in March 2021 recognizing the use of LUMIBIRD Medical products for
first-line treatments;
- The Japanese
health authorities’ approval of one of Quantel Medical’s flagship
products, the ophthalmic ultrasound solution ABSolu. This is now
available in Japan, the world’s second largest ophthalmology
market, through the Ellex subsidiary.
LUMIBIRD has successfully adapted its commercial
activity to the context of travel restrictions and industry events,
recording an acceleration in new orders at end-March. Moreover, the
Group has been relatively unaffected to date by the global tensions
surrounding electronics components, thanks to its high level of
industrial integration. LUMIBIRD is still confident about its
outlook for full-year growth and is confirming its three-year
objectives announced at the start of the year.
Next
date: 2021 first-half
revenues on July 26, 2021 (after close of trading)
LUMIBIRD is one of the world's leading
specialists in lasers. With 50 years of experience and a mastering
of solid state laser, laser diodes and fiber laser technologies,
the Group designs, manufactures and markets high performance lasers
for scientific (laboratories and universities), industrial
(manufacturing, defense, Lidar sensors) and medical (ophthalmology,
ultrasound diagnostic) markets.
Born from the combination of Keopsys Group with
Quantel in October 2017, LUMIBIRD has more than 800 employees and
over €126 million of consolidated revenues in 2020 and is present
in Europe, America and Asia.
LUMIBIRD shares are listed on the
Euronext Paris B Compartment. FR0000038242 –
LBIRD www.lumibird.com
Contacts
LUMIBIRDMarc Le FlohicChairman and CEOTel. +33(0) 1 69 29 17
00info@lumibird.com |
LUMIBIRDAude Nomblot-GourhandSecretary General – CFOTel. +33(0) 1
69 29 17 00info@lumibird.com |
CalyptusMathieu CalleuxInvestors RelationsTel. +33(1) 53 65 37
91lumibird@calyptus.net |
1 Including Ellex at January 1, 2020
- 210426LumibirdCAT12020EN_erratum
Grafico Azioni Lumibird (EU:LBIRD)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Lumibird (EU:LBIRD)
Storico
Da Apr 2023 a Apr 2024